3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Status
Active not recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Other hematologic neoplasm
1
Conditions
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Rituximab
21
Cyclophosphamide
18
Prednisone
14
Doxorubicin
12
Magnetic Resonance Spectroscopy
11
Lenalidomide
11
Vincristine
10
Specimen Handling
10
Biopsy
7
Gemcitabine
6
pembrolizumab
5
obinutuzumab
5
ibrutinib
5
Oxaliplatin
5
prednylidene
4
polatuzumab vedotin
4
glofitamab
4
deltacortene
4
Prednisolone
4
Dexamethasone
4
CT-P10
4
venetoclax
3
tafasitamab
3
fludarabine
3
acalabrutinib
3
R-CHOP protocol
3
Nivolumab
3
Immunotherapy, Adoptive
3
Etoposide
3
selinexor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Lymphoma, Large B-Cell, Diffuse
×
R-CHOP protocol
×
30 days
×
Clear all
NCT04661007
2026-05-18
J-MIND
Incyte Corporation
Phase 1/2
Active not recruiting
72 enrolled
NCT04542824
2026-05-05
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled
NCT04663347
2026-05-05
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2
Active not recruiting
543 enrolled